Abnormal activation of the PI3K/AKT/mTOR pathway is observed in 30.5% of HNSCC patients, and clinical trial results show that targeting PI3K/AKT/mTOR pathway‐related components can inhibit the metastasis, expansion, and deterioration of HNSCC. The gene discussed is MTOR; the disease is head and neck squamous cell carcinoma.